Results 171 to 180 of about 490,601 (215)

Anesthesia for Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

2021
HIPEC is a highly concentrated, heated chemotherapy treatment that is delivered directly into the abdominal cavity after cytoreductive surgery (CRS). Anesthetic management for Cytoreductive surgery (CRS) with HIPEC (hyperthermic intraperitoneal chemotherapy) involves multiple challenges including the patient’s preoperative health status, disease load ...
Eilish M. Galvin, Emma C. Boer, Sanne H. Hidding   +2 more
openaire   +1 more source

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Techniques

2015
Peritoneal carcinomatosis has long been considered a terminal condition and constitutes a difficult therapeutic challenge given the dismal prognosis associated with this entity and the debilitating effect it exerts on affected patients. Over the past decade, novel therapeutic approaches to peritoneal surface malignancies have emerged.
Salvatore Virzì, Domenico Rosario Iusco, Serena Bonomi, Antonio Grassi   +3 more
openaire   +1 more source

Toxicities and doses of chemotherapy drugs in hyperthermic intraperitoneal chemotherapy (HIPEC).

Journal of Clinical Oncology, 2015
e13524 Background: Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) to treat mucinous intra-abdominal tumors began in 1980.1 More recently, the combination of complete cytoreductive surgery and ...
Samuel Danial Pandiyan, Samuel J. Friedman, Wim P. Ceelen   +2 more
openaire   +1 more source

Rationale for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment or Prevention of Peritoneal Carcinomatosis

Acta Chirurgica Belgica, 2004
Up to now, the prognosis of peritoneal carcinomatosis from GI tract cancers remains very poor. Intraperitoneal hyperthermic chemotherapy has been proposed in the prevention or treatment of peritoneal carcinomatosis. The rationale for this locoregional approach comes from a better knowledge of the physiopathology of the disease.
Detroz, Bernard, Laurent, Stanislas, Honore, Pierre, Blaffart, Francine, Limet, Raymond, Meurisse, Michel   +5 more
openaire   +2 more sources

Investigations on Safety of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) With Mitomycin C

European Journal of Surgical Oncology, 2006
Previous safety monitoring of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C (MMC) did not demonstrate any detectable safety hazard to the personnel. Nevertheless, those results have been discussed controversially because of the methodological problems employed in the evaluation of potential exposure.
H Drexler, J Angerer, K Schmid
exaly   +3 more sources

Cytoreductive Surgery and “Hyperthermic Intraperitoneal Chemotherapy (HIPEC)”

2016
For a long time malignant tumor manifestation of the peritoneum, peritoneal carcinomatosis (PC) was regarded as terminal. This meant that both medical and surgical palliation treatments came into question which aimed to keep quality of life as long as possible. These methods are known as “best supportive care.”
Markus Hirschburger, Winfried Padberg
openaire   +1 more source

Robotic-assisted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)

Journal of Robotic Surgery, 2018
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an appropriate treatment for select patients with peritoneal carcinomatosis. While most commonly performed through an open incision, the laparoscopic approach has been reported and offers short-term benefits.
Emmanuel Gabriel, Enrique Elli, Sanjay Bagaria, Nabil Wasif, Travis Grotz, John Stauffer, Pashtoon M. Kasi, Horacio Asbun   +7 more
openaire   +2 more sources

Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Surgical Oncology, 2016
Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is increasingly used in the treatment of peritoneal malignancies. The administration of HIPEC after complete cytoreduction offers the combination of the pharmacokinetic advantages inherent to the intraperitoneal delivery of cytotoxic chemotherapy, with the direct ...
Ioannis, Kyriazanos, Vasileios, Kalles, Anastasios, Stefanopoulos, John, Spiliotis, Faheez, Mohamed   +4 more
openaire   +2 more sources

Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study

Annals of Surgical Oncology, 2018
The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improved the prognosis of selected patients with peritoneal mesothelioma (PM).The objective of our study was to evaluate whether different HIPEC agents were associated with different outcomes in patients with PM.From the RENAPE database,
Malgras, Brice, Gayat, Étienne, Aoun, Olivier, Lo Dico, Réa, Eveno, Clarisse, Pautrat, Karine, Delhorme, Jean-Baptiste, Passot, Guillaume, Marchal, Frédéric, Sgarbura, Olivia, Ferron, Gwenaël, Goéré, Diane, André, Thierry, Pocard, Marc   +13 more
openaire   +4 more sources

The Role of Laparoscopy in Peritoneal Surface Malignancies Selected for Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Annals of Surgical Oncology, 2012
Cytoreductive surgery (CS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was developed as locoregional treatment for primary or secondary peritoneal tumors. The role of laparoscopy over several stages of diagnosis and the treatment of the patients affected by peritoneal carcinomatosis and selected for CS + HIPEC shows some ...
SOMMARIVA, ANTONIO, Zagonel V, ROSSI, CARLO RICCARDO   +2 more
openaire   +2 more sources